



Aspirin and clopidogrel resistance: an emerging clinical entity

Thomas H. Wang, Deepak L. Bhatt*, and Eric J. Topol

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA

Received 14 July 2005; revised 26 October 2005; accepted 24 November 2005

KEYWORDS

Aspirin;
Clopidogrel;
Aspirin resistance;
Clopidogrel resistance

Antiplatelet therapy is a cornerstone of cardiovascular medicine. Aspirin and clopidogrel have emerged as critical therapies in the treatment of cardiovascular disease. Despite their efficacy, patients on these medications continue to suffer complications. Millions of patients are currently on low-dose antiplatelet therapy but it is unknown how many of these patients are under-treated or on the wrong medication. Aspirin and clopidogrel resistance are emerging clinical entities with potentially severe consequences such as recurrent myocardial infarction, stroke, or death. The mechanism of resistance remains incompletely defined, but there are specific clinical, cellular, and genetic factors that influence therapeutic failure. These factors range from physicians who fail to prescribe these medications despite appropriate indications to polymorphisms of platelet membrane glycoproteins. Rapid and accurate diagnosis of antiplatelet resistance also remains an issue as new bedside tests are developed. By understanding the mechanism of therapeutic failure and by improving the diagnosis of this clinical entity, a new era of individualized antiplatelet therapy may arise with routine measurements of platelet activity in the same way that cholesterol, blood pressure, and blood sugar are followed, thus improving the care for millions of people.

Introduction

Antiplatelet therapy is a cornerstone of cardiovascular medicine. Clinical trials have shown the efficacy of aspirin in both the primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death.^{1,2} The Antithrombotic Trialists' Collaboration found an approximately 25% reduction in stroke, myocardial infarction, or cardiovascular death.² The Second International Study of Infarct Survival (ISIS-2) trial demonstrated that acute aspirin use reduced mortality by 23% in acute ST-elevation myocardial infarction.³ Aspirin was shown to be equally efficacious as thrombolytic therapy while having an additive benefit when used in conjunction with streptokinase.

The thienopyridine clopidogrel has significant antiplatelet effect by inhibiting adenosine diphosphate (ADP)-mediated platelet activation. The Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study compared clopidogrel with aspirin in a wide spectrum of patients at risk for atherothrombosis. Initial analysis revealed a statistically significant 8.7% ($P = 0.043$) relative risk reduction in stroke, myocardial infarction, or ischaemic death in patients treated with clopidogrel.⁴ Further work has shown an even larger impact on high-risk populations such as patients with a previous coronary artery bypass graft, with a

history of ≥ 1 ischaemic event, diabetes, hypercholesterolaemia, or with disease in multiple vascular beds.⁵

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial found that dual antiplatelet therapy with clopidogrel and aspirin in acute coronary syndromes (ACSs) reduced adverse coronary events by 20% when compared with aspirin monotherapy.⁶ The PCI-CURE sub-study and the Clopidogrel for the Reduction of Events During Observation (CREDO) trial investigated the use of pretreatment and long-term treatment with clopidogrel following stenting. PCI-CURE showed a 30% relative risk reduction in the primary endpoint of MI, urgent revascularization, or cardiovascular mortality at 30 days and showed further benefit from prolonged administration.⁷ CREDO demonstrated a 26.9% relative risk reduction in cardiovascular risk at 1 year and also showed the efficacy of clopidogrel pretreatment in certain patients undergoing PCI.⁸

The Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY-TIMI-28) study evaluated clopidogrel in conjunction with aspirin, anticoagulation, and thrombolytics in ST-elevation myocardial infarction. This study revealed a 20% relative risk reduction in death, recurrent myocardial infarction, and recurrent ischaemia in patients who received clopidogrel as opposed to placebo.⁹ The Clopidogrel and Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study (COMMIT/CCS-2) enrolled nearly 46 000 patients receiving aspirin and compared the use of 75 mg of clopidogrel to placebo in patients with an ST-elevation

* Corresponding author. Tel: +1 216 445 4042; fax: +1 216 445 8531.
E-mail address: bhattedd@ccf.org

myocardial infarction. The results complemented that of CLARITY-TIMI-28 by showing a 9% relative risk reduction of death, myocardial infarction or stroke; the reduction in mortality alone was 7%. COMMIT/CCS-2 additionally had an upper age limit of 100 years on patient enrolment as opposed to 75 years in the CLARITY trial, thus supporting the use of clopidogrel in an older population.¹⁰ Importantly, both trials showed the effectiveness of therapy without an increased rate of major bleeding.

In terms of primary prevention, aspirin has been evaluated in six randomized trials.¹¹⁻¹⁶ The Physicians Health Study showed a 44% risk reduction in first myocardial infarction among physicians treated with aspirin.¹¹ The Thrombosis Prevention Trial (TPT) revealed the utility of aspirin in men at high-risk for coronary disease,¹³ whereas the Hypertension Optimal Treatment (HOT) trial demonstrated a 36% reduction of myocardial infarction in hypertensive patients treated with aspirin.¹⁴ The Primary Prevention Project (PPP) extended the findings of these trials by showing a 56% relative reduction in cardiovascular death in men and women with one or more major cardiovascular risk factors treated with aspirin.¹⁵ Interestingly, the underpowered British Doctors' Study found no significant benefit to aspirin therapy.¹² A meta-analysis of these five trials evaluated a combined 55 580 patients and found a 32% relative risk reduction of having a first myocardial infarction in treated patients.¹⁷ The Women's Health Study randomized 39 876 females to low-dose aspirin therapy and showed no significant reduction in myocardial infarction though there was a significant relative risk reduction in total and ischaemic stroke.¹⁶ However, a subgroup analysis revealed a significant benefit in women older than 65 years of age.

On the basis of these and other studies, aspirin and clopidogrel have emerged as critical therapies in both the primary and secondary prevention of coronary artery disease. The studies underscore the importance of

controlling platelet reactivity as well as systemic inflammation, and these medications provide a foundation for antiplatelet therapy in coronary disease. Importantly, the studies stimulate new questions regarding the aetiology of therapeutic failure. Millions of patients worldwide currently take low-dose aspirin. Despite its benefits, many patients continue to suffer the effects of cardiovascular disease. By understanding the mechanism of treatment failure, therapeutic regimens can be changed and thus critically alter patient outcomes.

This review of the literature was performed via PubMed and Medline using the terms 'aspirin resistance' and 'clopidogrel resistance.' In addition, relevant journals were hand-searched for recently presented data from national cardiology conferences.

Mechanisms of failed therapy

Aspirin works by irreversibly acetylating the cyclooxygenase (COX)-1 enzyme, thus suppressing thromboxane A_2 .¹⁸ Thromboxane A_2 serves as a potent agonist of platelet aggregation, and aspirin prevents thrombus formation via this mechanism. However, its antiplatelet effect is not uniform in all patients¹⁹ and its inhibition of platelet aggregation is subject to inter-individual and intra-individual variability.²⁰ This unpredictable response to aspirin can be attributed to clinical, cellular, and genetic factors.²¹

Clinical causes of aspirin resistance can range from patient non-compliance to physicians who display aspirin resistance, that is, physicians who fail to prescribe aspirin appropriately (*Figure 1*).^{21,22} Alternatively, patients may take aspirin but not absorb it, or may have interactions because of other medications. Ibuprofen, for example, can adhere to the COX-1 binding site of aspirin, and may via steric hindrance prevent aspirin from exerting its antiplatelet effect and limit its cardioprotective function.²³ The dose




Figure 1. Mechanisms of aspirin resistance. [adapted from *Journal of the American College of Cardiology*, 43, Bhatt, DL. Aspirin resistance: more than just a laboratory curiosity, 1128, 2005].

of aspirin may contribute to uninhibited platelet activity depending on the weight and age of patients.²⁴

In addition, ACSs and congestive heart failure are associated with increased platelet reactivity.²⁵ Hyperglycaemia may decrease the effectiveness of antiplatelet therapy by increasing reactive oxidant species,²⁶ whereas hypercholesterolaemia may blunt aspirin's effect on thrombin.^{27,28} Exercise and the catecholamine surge associated with stress can also affect platelet responsiveness.²⁹

Cellular factors influencing aspirin efficacy include inadequate suppression of platelet COX-1. In addition, aspirin resistance has been attributed to COX-2 mRNA over-expression by platelets and endothelial cells, though this remains controversial.^{30,31} 8-iso-PGF₂ generation by catalysed arachidonate peroxidation may also cause aspirin resistance by binding thromboxane receptors.³² Resolvins, a family of bioactive omega-3 fatty acid metabolites, mediate the inflammatory response and are generated via COX-2 acetylation by aspirin.³³ A deficiency of these products could also influence therapeutic failure.

Genetics also play a role in patient response to aspirin as polymorphisms of platelet membrane glycoproteins such as P1 (A1/A2) have been associated with an attenuated response to aspirin.^{34,35} Polymorphisms of von Willebrand Factor (vWF) or the collagen receptor gene have also been postulated to cause aspirin resistance.^{36,37} Single nucleotide polymorphisms of the P₂Y₁ gene also can affect response to aspirin.³⁸ Despite these findings, the impact of polymorphisms on aspirin response remains controversial.³⁹

Clopidogrel resistance may also be because of clinical, cellular, and genetic factors. Clopidogrel is a prodrug that is converted in the liver by cytochrome P450 3A4 (CYP3A4) into its active metabolite. It inhibits platelet aggregation by irreversibly binding to the P₂Y₁₂ ADP receptor on the platelet surface. Similar to aspirin, clopidogrel therapy may fail owing to patient non-compliance or because physicians may not prescribe it. In addition, there may be variability in absorption⁴⁰ with associated under-dosing in patients and possible drug-drug interactions.⁴¹ A recent

study correlated the level of angina class with platelet inhibition by clopidogrel and found that patients with higher Braunwald angina class had lower inhibition of platelet aggregation.⁴²

A recent analysis has raised the possibility of an interaction between atorvastatin and clopidogrel.⁴³ Analysis of the CREDO trial, found that this was not clinically significant and that the benefit of clopidogrel was similar with all statins regardless of the metabolic mechanism.⁴⁴ Other data, from the Plavix for Reduction of New Thrombotic Occurrences (PRONTO) study and the Interaction of Atorvastatin and Clopidogrel Study (Interaction) have shown that statins including atorvastatin do not interfere with platelet inhibition by clopidogrel.^{45,46} Additional studies investigating the use of high-dose clopidogrel (600 mg) with statins has shown a lack of interaction between the agents.^{47,48}

Cellular mechanisms of clopidogrel resistance may be because of inter-individual differences in P₂Y₁₂ receptors and the number of receptors an individual possesses, varying the levels of ADP release, or platelet activation via alternative pathways. Notably, the degree of platelet responsiveness in patients treated with clopidogrel has been found to follow a normal bell-shaped curve (*Figure 2*).⁴⁹ Two small studies investigated the use of a 300 mg loading dose of clopidogrel immediately after stenting and found highly variable levels of responsiveness among individuals.^{50,51} The durability of platelet inhibition by clopidogrel has also been studied showing the sustained antiplatelet effect of clopidogrel after 5 days, but also a significant heterogeneous response to the medication.⁵² In terms of genetics, the H2 haplotype of the P₂Y₁₂ receptor was associated with a more substantial down-regulation of platelet cyclic AMP because of ADP, which potentially could lead to a greater risk of thrombotic events.^{53,54} A recent study noted, however, that the H2 haplotype did not adversely affect platelet inhibition by high-dose clopidogrel.⁵⁵ Eventually, analysis of the human genome may reveal previously undefined mechanisms of platelet resistance as well.




Figure 2. Variability in platelet responsiveness to clopidogrel among 544 individuals. Distribution of 5 µM of ADP-induced residual platelet aggregation in 544 patients after receiving clopidogrel therapy. [Reprinted from *Journal of the American College of Cardiology*, 45, Serebrany, Victor L., Steinhubl, Steven R., Berger, Peter B., Malinin, Alex I., Bhatt, Deepak L., Topol, Eric J. Variability in Platelet Responsiveness to Clopidogrel Among 544 Individuals, 247, 2005, with permission from the American College of Cardiology Foundation].

Aspirin and clopidogrel resistance may also be caused because platelet reactivity is mediated via the thromboxane A₂ and ADP-pathways. A sufficient stimulus for platelet aggregation (i.e. thrombin) may in fact overcome the inhibition of these pathways. In addition, human platelets have a variable response to agonists such as ADP, epinephrine, and others.⁵⁶ Similarly, platelets exhibit variable responsiveness to drug-related inhibition as well.⁵⁷ Acquired forms of aspirin response variability also play a role in terms of ACSs and systemic inflammation.^{58,59}

Defining resistance

As the mechanisms of aspirin and clopidogrel resistance are becoming clearer, defining these clinical entities remains a challenge. In its broadest sense, resistance refers to the continued occurrence of ischaemic events despite adequate antiplatelet therapy and compliance. The lack of a standard definition of resistance as well as the lack of a standard diagnostic modality has hampered the field in identifying and treating this clinical entity. Attempts have been made to develop a more meaningful definition with the goal of correlating laboratory tests with clinical outcomes, but there is no current definition which unifies the biochemical and clinical expression of failed treatment.⁶⁰⁻⁶⁵ Rates of aspirin resistance range from 5 to 45% of the population depending on the study and the method of determining therapeutic failure.⁶⁶⁻⁶⁹ Rather than attempting to characterize patients as simply resistant or sensitive to a medication, however, therapeutic resistance is more likely a continuous variable similar to blood pressure. By shifting the paradigm of diagnosis from a specific value to this notion of a continuous variable, the physiology of treatment failure may be better elucidated and thus better managed. In the meantime, a clear and consistent characterization of antiplatelet resistance is necessary.

In terms of diagnostic testing, light transmittance aggregometry is the current gold standard for determining platelet function. Unfortunately, this technique is labour intensive and requires the assay to be performed in a

laboratory, thus preventing bedside assessment. In addition, differences in technique and proficiency between laboratories can make data from varying institutions difficult to interpret.^{70,71}

The platelet function analyzer (PFA)-100 (Dade-Behring, Deerfield, IL), and the VerifyNow Rapid Platelet Function Assay (RPFA)-ASA (Accumetrics, San Diego, CA) have been designed as point-of-care tests to allow ease of use and widespread distribution (*Table 1*). The PFA-100 test has variable correlation with the historical gold standard of light-transmittance aggregometry and requires further study in order to determine its clinical relevance.^{72,73} The VerifyNow RPFA-ASA assay has shown excellent correlation with optical aggregometry using whole blood but requires investigation into the clinical impact of resistance (defined as an aspirin resistance unit or ARU of >550) and the rate of subsequent cardiovascular events.⁷⁴ Urinary levels of 11-dehydrothromboxane B₂ have also been utilized to study aspirin inhibition of thromboxane generation though it is not known whether the persistent elevation in urinary thromboxane B₂ levels is because of uninhibited platelet COX-1 activity or by COX-1 independent sources of thromboxane generation.^{63,75,76}

What are the consequences of aspirin or clopidogrel resistance?

Eikelboom *et al.*⁷⁶ measured urinary 11-dehydro thromboxane B₂ levels in patients on aspirin from the Heart Outcomes Prevention Evaluation (HOPE) study. Patients in the highest quartile of urinary 11-dehydro thromboxane B₂ levels had a 1.8 times higher risk of myocardial infarction, stroke, or cardiovascular death than patients in the lowest quartile ($P = 0.009$). Gum *et al.*⁶⁶ performed a randomized prospective trial of 326 patients on aspirin and no other antiplatelet agents. Aspirin sensitivity was tested by optical platelet aggregation, considered the gold standard in determining platelet response. Of those studied, 17(5%) patients were found to be aspirin-resistant and in follow-up had

Table 1 Laboratory assays for aspirin and clopidogrel resistance

Lab method	Pros	Cons
Light transmittance aggregometry	Considered gold standard Monitors aspirin, thienopyridines, and IIB/IIIA inhibitors	Time-consuming Cannot be run at bedside Variable results depending on reagents used
Platelet Function Analyzer (PFA)-100	Allows for bedside analysis Easy to use and rapid Whole blood assay	Depends on vWF and haematocrit Monitors only aspirin (not thienopyridines or IIB/IIIA inhibitors)
VerifyNow Rapid Platelet Function Assay	Allows for bedside analysis Easy to use and rapid Whole blood assay Monitors aspirin, thienopyridines, ^a and IIB/IIIA inhibitors	
Urinary 11-dehydrothromboxane B ₂	COX-1 dependent	Indirect measure Not platelet-specific Depends on renal function Monitors only aspirin (not thienopyridines or IIB/IIIA inhibitors)

^aRapid Platelet Function Assay is now FDA approved for clopidogrel.

a nearly three-fold increased risk of death, myocardial infarction, or CVA ($P = 0.03$).⁶⁶

More recently, Chen *et al.* investigated the effect of aspirin resistance on myonecrosis after non-urgent percutaneous coronary intervention (PCI) among 151 patients pretreated with 300 mg of clopidogrel >12 h prior to PCI and 75 mg the morning of the PCI. The point-of-care VerifyNow RPFA test was utilized to determine therapeutic responsiveness. Twenty-nine patients (19.2%) were found to be aspirin-resistant with an increased risk of myonecrosis (51.7% vs. 24.6% as assessed by troponin elevation, $P = 0.006$) following non-urgent PCI, despite pretreatment with aspirin.⁷⁷

Clopidogrel resistance has been studied in patients with acute myocardial infarction confirming the inter-individual variability of platelet inhibition by clopidogrel. Matetzky *et al.*⁷⁸ analysed 60 patients with acute ST-segment myocardial infarction who underwent primary PCI and were subsequently placed on clopidogrel. Patients were divided into quartiles of responsiveness to clopidogrel measured by the percent reduction of ADP-induced platelet aggregation. The patients who were least responsive to therapy determined by aggregometry were 25% more likely to have a recurrent cardiovascular event during a 6-month follow-up when compared with patients in the other three quartiles of platelet responsiveness ($P = 0.007$). In addition, clopidogrel use post-PCI for stable angina has been evaluated, with a higher rate of subacute stent thrombosis found in clopidogrel non-responders.⁷⁹

On the basis of these studies, the risk of therapeutic failure to antiplatelet therapy is concerning. Patients are at increased risk for cardiovascular complications including death, myocardial infarction, and cerebrovascular accidents. Thus, the need for additional investigation into the clinical consequences of these laboratory findings remains vital, as the data presented earlier must be reproduced in larger datasets. Given the consequences of therapeutic failure, the question thus turns to how a clinician can effectively treat resistance to antiplatelet agents.

Treating aspirin and clopidogrel resistance

The treatment for failed antiplatelet therapy is as yet undefined. An initial approach would be to correct the clinical factors that may cause therapeutic resistance. Physicians must ensure proper patient compliance while also minimizing drug-drug interactions. In addition, optimal control of glucose levels and cholesterol levels can reduce platelet reactivity.

Currently, there is no good evidence that increasing aspirin dose would be useful.² Data from Blockage of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial and the CURE trial actually indicate an increased risk of serious bleeding associated with high aspirin doses.^{67,80} However, it remains possible, though unproven, that increased doses of aspirin may overcome aspirin resistance in an individual patient. The addition of clopidogrel to aspirin is logical given its distinct mechanism of action. The Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study revealed modest superiority of clopidogrel monotherapy over aspirin monotherapy,⁴ while also showing an increased benefit in high-risk patients.⁶⁸ In terms of dual antiplatelet therapy, aspirin

resistant patients have platelets that are more sensitive to ADP.⁸¹ The CURE and CREDO trials support this notion as they revealed the additive clinical benefit of clopidogrel to aspirin.

Beyond the use of aspirin in conjunction with clopidogrel, the options for medical therapy remain limited. Consideration can be given to increasing maintenance doses or loading doses of clopidogrel.^{82,83} The Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty (ARMYDA-2) study showed the benefit of 600 mg of clopidogrel when compared with 300 mg of clopidogrel as pretreatment in reducing periprocedural myocardial infarction in patients undergoing PCI.⁸⁴ The utility of increasing the dose of clopidogrel has been further supported by the recent findings in the Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation, and Ongoing Necrosis (ALBION) trial.⁸⁵ Additionally, the Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect trial (ISAR-CHOICE) has been recently published and showed a greater and faster degree of platelet inhibition with a 600 mg versus a 300 mg loading dose of clopidogrel.⁸⁶

Alternative thienopyridine agents are also possibilities as CS-747, also known as prasugrel (LY640315)⁸⁷ and non-thienopyridine P₂Y₁₂ inhibitors such as the intravenous agent cangrelor⁸⁸⁻⁹⁰ and the oral ADP antagonist AZD6140 are still under investigation. CS-747 has already been investigated in a large phase-2 study, Joint Utilization of Medications to Block Platelets Optimally—Thrombolysis in Myocardial Infarction 26 (JUMBO-TIMI-26), and was found to have low rates of clinical bleeding.⁹¹ Other studies have shown the potential benefit of cangrelor as an adjunct to fibrinolysis in acute myocardial infarction as well as in facilitated angioplasty.^{92,93} In addition, cangrelor has potent platelet inhibition which may be greater than clopidogrel, has a short plasma half-life, does not require hepatic activation, and is a direct antagonist of the P₂Y₁₂ receptor.⁹⁴ AZD6140 is an oral P₂Y₁₂ antagonist which blocks platelet aggregation more completely than clopidogrel and also does not require hepatic metabolism for activation.

Looking to the future

As the understanding of antiplatelet resistance improves, more options become available for diagnosing and treating this clinical entity. The need for larger trials that correlate clinical outcomes data with laboratory assessment of platelet aggregability has been underscored by the adverse results seen in patients with aspirin or clopidogrel resistance (Table 2).^{66,76,78,95} Such efforts are currently underway as part of the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management, and Avoidance (CHARISMA) Trial. This randomized, international, double-blinded, placebo controlled trial will follow 15 603 patients who receive either clopidogrel and aspirin or placebo and aspirin for high-risk primary or secondary prevention.^{96,97} The primary endpoints will be vascular death, myocardial infarction, or stroke. In a substudy, DNA samples will be obtained from patients and can help identify single nucleotide polymorphisms that may contribute to aspirin or clopidogrel resistance. Also in a substudy, urinary 11-dehydrothromboxane B₂ levels will be checked, thus prospectively

Table 2 Future trials

CHARISMA	Investigates the additive benefit of clopidogrel to aspirin for high-risk primary or secondary prevention
Substudy	DNA samples will be obtained to help identify single nucleotide polymorphisms contributing to aspirin and clopidogrel resistance
Substudy	Urinary 11-dehydro thromboxane B2 levels will be checked to assess the clinical risk associated with aspirin resistance and whether clopidogrel decreases this risk
RESISTOR	Investigates the use of the VerifyNow assay in determining patient response to aspirin and clopidogrel and whether non-responders have benefit with IIB/IIIA inhibitors
TRITON-TIMI 38	Evaluates prasugrel compared with clopidogrel in patients with ACS undergoing PCI

assessing whether clopidogrel added to aspirin attenuates the clinical risk associated with aspirin resistance.

Another study, the Research Evaluation to Study Individuals who Show Thromboxane or P₂Y₁₂ Receptor resistance (RESISTOR) trial, will investigate the use of clopidogrel in addition to aspirin prior to elective angioplasty. The trial will utilize the VerifyNow Rapid Platelet Function Analyzer to identify patients as responders or non-responders and then randomize patients to the intravenous glycoprotein IIb/IIIa inhibitor eptifibatid plus unfractionated heparin or unfractionated heparin alone.

The JUMBO-TIMI-26 trial has prompted a phase-3 evaluation of prasugrel vs. clopidogrel in patients with ACSs undergoing PCI. This study, entitled TRITON-TIMI-38, will have a target enrolment of 13 000 patients and have a primary composite endpoint of cardiovascular death, myocardial infarction, or stroke.⁹¹ The DISPERSE2 study was a phase IIb study that investigated the efficacy of two different doses of AZD6140 (90 mg or 180 mg twice daily) compared to 75 mg of clopidogrel once daily in patients with non-ST elevation myocardial infarction. Results showed similar rates of bleeding in all groups and no significant difference in the composite endpoint of cardiovascular death, stroke, or recurrent ischemia. Based on this finding, further studies may be forthcoming regarding this new agent.⁹⁸

As more is learned about the variable response to antiplatelet drugs, the need for accurately assessing inter-individual response to such therapy increases. Millions of patients take low-dose aspirin for thromboprophylaxis today. How many are taking the wrong dose or the wrong drug? Given the wide range of possible aspirin resistance from 5 to 45%, a large population is at risk for inadequate or incorrect therapy. While the terms aspirin and clopidogrel resistance remain broadly defined, they represent valid biochemical entities with potentially very significant clinical consequences. The future may soon be realized with routine measurements of platelet activity in the same way that cholesterol, blood pressure, and blood sugar are followed to help guide therapy. A new era of individualized antiplatelet therapy may arise with differing doses and

differing therapeutic agents provided for the millions of patients receiving these treatments. However, ongoing and future trials will be necessary to validate this approach.

Conflict of interest: T.H.W. and E.J.T. have no conflicts of interest to report. D.L.B. has received honoraria for educational lectures and/or served on scientific advisory boards for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Millennium, Sanofi Aventis, Schering Plough, and The Medicines Company.

References

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994;**308**:81–106.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. *BMJ* 2002;**324**:71–86.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988;**332**:349–360.
4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996;**348**:1329–1339.
5. Hirsch J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations. *Arch Intern Med* 2004;**164**:2106–2110.
6. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;**345**:494–502.
7. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;**358**:527–533.
8. Steinhubl SR, Berger PB, Mann III JT, Fry ETA, DeLago A, Wilmer C, Topol EJ, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002;**288**:2411–2420.
9. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E, the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005;**352**:1179–1189.
10. Chen Z, Jiang L, Chen Y, Xie J, Pan H, Peto R, Collins R, Liu L. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005;**366**:1607–1621.
11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1989;**321**:129–135.
12. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. *Br Med J (Clin Res Ed)* 1988;**296**:313–316.
13. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet* 1998;**351**:233–241.
14. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998;**351**:1755–1762.
15. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. *Lancet* 2001;**357**:89–95.
16. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005;**352**:1293–1304.

17. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. *Arch Intern Med* 2003;163:2006-2010.
18. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. *Med Clin North Am* 2000;84:163-179.
19. Patrono C, Dalen JE, Fitzgerald GA, Fuster V, Gent M, Hirsch J. Platelet-active drugs. *Chest* 2001;119:395.
20. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser S. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. *Thromb Haemost* 2000;83:316-321.
21. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. *J Am Coll Cardiol* 2004;43:1127-1129.
22. Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, Hammill BG, McCants J, Charles B, Kramer JM. Underuse of aspirin in a referral population with documented coronary artery disease. *Am J Cardiol* 2002;89:653-661.
23. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, Fitzgerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med* 2001;345:1809-1817.
24. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. *J Am Coll Cardiol* 2005;46:1258-1263.
25. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay J-F, Steinhubl SR, O'Connor CM. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the plavix use for treatment of congestive heart failure (PLUTO-CHF) trial. *Am Heart J* 2003;146:713-720.
26. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. *Prostaglandins Leukot Essent Fatty Acids* 2002;66:557-558.
27. Szczeklik A, Musial J, Undas A, Swadzba J, Gora PF, Piwowarska W, Dupluga M. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. *Arterioscler Thromb Vasc Biol* 1996;16:948-954.
28. Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. *J Am Coll Cardiol* 1999;33:1286-1293.
29. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. *Thromb Res* 2003;108:115-119.
30. Weber AA, Zimmerman KC, Meyer-Kirchraht J, Schör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. *Lancet* 1999;353:900.
31. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber A-A, Gams E, Schror K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. *Circulation* 2003;108:542-547.
32. Davi G, Guagnano MT, Ciabattone G, Basili S, Falco A, Marinopicolli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. *JAMA* 2002;288:2008-2014.
33. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. *J Exp Med* 2002;196:1025-1037.
34. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. Resistance in vitro to low-dose aspirin is associated with platelet PLA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T kozak (GP Ib[alpha]) polymorphisms. *J Am Coll Cardiol* 2003;42:1115-1119.
35. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. P1(A2) Polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. *Circulation* 2001;104:2666-2672.
36. Pontiggia L, Lassila R, Pederiva S, Schmid H-R, Burger M, Beer JH. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIb/IIIa. *Arterioscler Thromb Vasc Biol* 2002;22:2093-2098.
37. Quinn M, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications. *Pharmacogenomics* 2001;2:341-352.
38. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, Topol EJ. Aspirin resistance and a single gene. *Am J Cardiol* 2005;95:805-808.
39. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. *Curr Opin Hematol* 2000;7:284-289.
40. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. *Thromb Haemost* 2004;92:311-316.
41. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. *Circulation* 2004;109:166-171.
42. Soffer D, Moussa I, Harjai K, Boura JA, Dixon SR, Grines CL, O'Neill WW, Roubin GS, Moses JW. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? *Catheter Cardiovasc Interv* 2003;59:21-25.
43. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. *Circulation* 2003;107:32-37.
44. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. *Circulation* 2003;108:921-924.
45. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. *Arch Intern Med* 2004;164:2051-2057.
46. Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. *Atherosclerosis* 2001;159:239-241.
47. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. *Circulation* 2005;111:2560-2564.
48. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. *Eur Heart J* 2004;25:1898-1902.
49. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. *J Am Coll Cardiol* 2005;45:246-251.
50. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation* 2003;107:2908-2913.
51. Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. *J Intern Med* 2002;252:233-238.
52. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. *Am J Cardiol* 2003;91:1123-1125.
53. Fontana P, Gaussem P, Aiach M, Fiessinger J-N, Emmerich J, Reny J-L. P2Y12 H2 Haplotype is associated with peripheral arterial disease: a case-control study. *Circulation* 2003;108:2971-2973.
54. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. *Circulation* 2003;108:989-995.
55. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. *Blood Coagul Fibrinolysis* 2005;16:199-204.
56. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. *Blood* 2005;106:2723-2729.
57. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. *J Thromb Haemost* 2005;3:1597-1602.
58. Ziegler S, Alt E, Brunner M, Speiser W, Minar E. Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients. *Ann Hematol* 2004;83:92-94.
59. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. *Thromb J* 2005;3:10.
60. Dhataria KK. Aspirin for everyone over 50? Don't forget aspirin resistance. *BMJ* 2005;331:161 (author reply 161).
61. Steinhubl SR, Charnigo R, Moliterno DJ. Resistance to antiplatelet resistance is it justified? *J Am Coll Cardiol* 2005;45:1757-1758.

62. Martin CP, Talbert RL. Aspirin resistance: an evaluation of current evidence and measurement methods. *Pharmacotherapy* 2005;**25**: 942-953.
63. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. *Rev Cardiovasc Med* 2004;**5**:156-163.
64. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. *J Thromb Haemost* 2003;**1**:1710-1713.
65. De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? *J Thromb Haemost* 2003;**1**:2048-2050.
66. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003;**41**: 961-965.
67. Topol EJ, Easton D, Harrington RA, Amarencu P, Califf RM, Graffagnino C, Davis S, Diener H-C, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. *Circulation* 2003;**108**:399-406.
68. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. *Circulation* 2001;**103**:363-368.
69. Chen W-H, Lee PY, Ng W, Yat-Yin Kwok J, Cheng X, Tse HF, Lau CP. Prevalence, profile, and predictors of aspirin resistance measured by the *Ultegra* rapid platelet function assay-ASA in patients with coronary artery disease. *J Am Coll Cardiol* 2005;**45**:382A.
70. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK. Assessment of platelet function assays. *Am Heart J* 1998;**135**:S170-S178.
71. Michelson AD. Platelet function testing in cardiovascular diseases. *Circulation* 2004;**110**:e489-e493.
72. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol* 2001;**88**:230-235.
73. Topol EJ, Gum P, Kottke-Marchant K. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: reply. *J Am Coll Cardiol* 2003;**42**:1336-1337.
74. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, Simon DI. Incidence of aspirin nonresponsiveness using the *Ultegra* rapid platelet function assay-ASA. *Am J Cardiol* 2003;**92**:1492-1494.
75. Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. *Proc Natl Acad Sci USA* 1986;**83**:5861-5865.
76. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation* 2002;**105**:1650-1655.
77. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol* 2004;**43**:1122-1126.
78. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation* 2004;**109**: 3171-3175.
79. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. *Thromb Haemost* 2003;**89**:783-787.
80. Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S, for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. *Circulation* 2003;**108**:1682-1687.
81. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. *Thromb Res* 2002;**107**:45-49.
82. Zidar FJ, Moliterno DJ, Bhatt DL, Kottke-Marchant K, Goormastic M, Plow EF, Topol EJ. High-dose clopidogrel loading rapidly reduces both platelet inflammatory marker expression and aggregation. *J Am Coll Cardiol* 2004;**43**:A64.
83. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. *Heart* 2001;**85**:92-93.
84. Patti G, Colonna G, Pasceri V, Pepe L, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) Study. *Circulation* 2005;**111**:2099-2106.
85. Montalescot G. Assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation, and ongoing necrosis (ALBION) Study. In: *EuroPCR*. Paris, France: 2005.
86. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolism, and antiplatelet effects of 300-, 600-, and 900- mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. *Circulation* 2005;**112**:2946-2950.
87. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. *Br J Pharmacol* 2000;**129**:1439-1446.
88. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J. Expert consensus document on the use of antiplatelet agents: the Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. *Eur Heart J* 2004;**25**:166-181.
89. Storey F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. *Platelets* 2001;**12**:197-209.
90. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. *Nat Rev Drug Discov* 2003;**2**:15-28.
91. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. *Circulation* 2005;**111**:3366-3373.
92. Asfour AI, Greenbaum AB, McFarland TM, LeMay M, Painter JA, Painter JA, Kieval J, Stebbins A, Weaver WD. Facilitated angioplasty with combined ADP P2T receptor blockade and fibrinolysis for the treatment of acute myocardial infarction: results from the STEP-AMI trial. *J Am Coll Cardiol* 2002;**39**:39.
93. Greenbaum AB, Ohman EM, Gibson MS, Borzak SL, LeMay M, Lu M, Stebbins AL, Emanuelsson H, Weavers WD. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction. *J Am Coll Cardiol* 2002;**39**:281.
94. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. *Platelets* 2002;**13**:407-413.
95. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol* 2004;**43**:1122-1126.
96. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am Heart J* 2004;**148**:263-268.
97. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am Heart J* 2005;**150**:401.
98. Cannon C, Husted S, Storey R, Harrington R, Watkins C, Hill S, Price D, Sanders N, Emanuelsson H, Peters G, for the DISPERSE 2 Investigators. The DISPERSE2 Trial: Safety, Tolerability and Preliminary Efficacy of AZD6140, the First Oral Reversible ADP Receptor Antagonist, Compared with Clopidogrel in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. In: *American Heart Association Scientific Sessions*. Dallas, TX: 2005.